View Financial HealthSynairgen 配当と自社株買い配当金 基準チェック /06Synairgen配当金を支払った記録がありません。主要情報n/a配当利回り-15.8%バイバック利回り総株主利回り-15.8%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Feb 27Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical StudySynairgen Limited announced its decision to terminate the ongoing global phase 2 clinical study. The study was designed to evaluate the efficacy and safety of SNG001 in mechanically-ventilated patients infected with a range of respiratory viruses. The first participant was entered into the study in December 2025. However, recruitment has been markedly behind expectations, and despite very active engagement and dialogue with the clinical sites it has been judged that the number of patients projected for a robust study readout is not feasible in a realistic timeframe. There are a number of reasons for this significantly low patient recruitment, not least the very low intensity of the winter viral season; which although prevalent in the community, did not result in a significant number of patients being admitted to intensive care and requiring invasive mechanical ventilation. A comprehensive review of alternative phase 2 study design options has been carefully conducted by the Synairgen management team, with material input from external clinical, regulatory and drug development experts. However, after careful deliberation, none of these options were considered feasible as they lacked the necessary combined attributes of delivering a material value-inflection generating readout in a realistic timeframe, and all demanded significant additional funding. Tetragon Partners, on behalf of certain funds and managed accounts to which it acts as investment manager (and who own the majority of the Company's shares), has confirmed that it would not provide further financing to the Company and has recommended that the Company instead focus on returning the maximum available funds to its shareholders. The Company's Board of Directors have carefully reviewed various strategic alternatives and have considered the current financing environment, clinical development data outputs and timelines, and the capital requirements of the Company. The Company has determined that it is not in a position to secure the additional significant funding required or a strategic partnership necessary to continue its operations. Accordingly, given that SNG001 is the sole asset of the business, the Board recommends that it is in the best interests of all shareholders that it now advances plans to wind down its operations and returns available cash to shareholders. The Company therefore plans to begin an orderly wind-down of operations, including meeting its obligations to shareholders, employees, creditors, vendors, and stakeholders in accordance with applicable laws and contractual commitments. Further to the Business Update published on 4 September 2025 and given the current status of the Company, it will not be holding an auction via the Asset Match platform. Meanwhile, the Company will explore whether there is any opportunity to divest certain intellectual property assets related to SNG001 although there is no guarantee that this will be successful. The Company will share further details with shareholders regarding the wind-down process in due course, including any shareholder approvals which may be required to approve it.お知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdomお知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.お知らせ • Oct 05Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical OfficerSynairgen plc announces the appointment of Dr. Marcin Mankowski as Chief Medical Officer (CMO), effective immediately. Marcin is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. Marcin joins Synairgen on a full-time basis having worked with the Company as acting CMO and a clinical trials consultant since 2018. Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United Kingdom決済の安定と成長配当データの取得安定した配当: SYGG.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SYGG.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Synairgen 配当利回り対市場SYGG.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SYGG.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (SYGG.F) (最長3年)n/a注目すべき配当: SYGG.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SYGG.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SYGG.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SYGG.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 15:19終値2026/03/09 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synairgen plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCavendishMark BrewerCavendish
お知らせ • Feb 27Synairgen Limited Announces Its Decision to Terminate the Ongoing Global Phase 2 Clinical StudySynairgen Limited announced its decision to terminate the ongoing global phase 2 clinical study. The study was designed to evaluate the efficacy and safety of SNG001 in mechanically-ventilated patients infected with a range of respiratory viruses. The first participant was entered into the study in December 2025. However, recruitment has been markedly behind expectations, and despite very active engagement and dialogue with the clinical sites it has been judged that the number of patients projected for a robust study readout is not feasible in a realistic timeframe. There are a number of reasons for this significantly low patient recruitment, not least the very low intensity of the winter viral season; which although prevalent in the community, did not result in a significant number of patients being admitted to intensive care and requiring invasive mechanical ventilation. A comprehensive review of alternative phase 2 study design options has been carefully conducted by the Synairgen management team, with material input from external clinical, regulatory and drug development experts. However, after careful deliberation, none of these options were considered feasible as they lacked the necessary combined attributes of delivering a material value-inflection generating readout in a realistic timeframe, and all demanded significant additional funding. Tetragon Partners, on behalf of certain funds and managed accounts to which it acts as investment manager (and who own the majority of the Company's shares), has confirmed that it would not provide further financing to the Company and has recommended that the Company instead focus on returning the maximum available funds to its shareholders. The Company's Board of Directors have carefully reviewed various strategic alternatives and have considered the current financing environment, clinical development data outputs and timelines, and the capital requirements of the Company. The Company has determined that it is not in a position to secure the additional significant funding required or a strategic partnership necessary to continue its operations. Accordingly, given that SNG001 is the sole asset of the business, the Board recommends that it is in the best interests of all shareholders that it now advances plans to wind down its operations and returns available cash to shareholders. The Company therefore plans to begin an orderly wind-down of operations, including meeting its obligations to shareholders, employees, creditors, vendors, and stakeholders in accordance with applicable laws and contractual commitments. Further to the Business Update published on 4 September 2025 and given the current status of the Company, it will not be holding an auction via the Asset Match platform. Meanwhile, the Company will explore whether there is any opportunity to divest certain intellectual property assets related to SNG001 although there is no guarantee that this will be successful. The Company will share further details with shareholders regarding the wind-down process in due course, including any shareholder approvals which may be required to approve it.
お知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.
お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdom
お知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.
お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.
お知らせ • Oct 05Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical OfficerSynairgen plc announces the appointment of Dr. Marcin Mankowski as Chief Medical Officer (CMO), effective immediately. Marcin is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. Marcin joins Synairgen on a full-time basis having worked with the Company as acting CMO and a clinical trials consultant since 2018. Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.
お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United Kingdom